{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:20:22Z","timestamp":1787898022703,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002418","name":"Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences and Peking Union Medical College","doi-asserted-by":"publisher","award":["2024-I2M-ZD-001"],"award-info":[{"award-number":["2024-I2M-ZD-001"]}],"id":[{"id":"10.13039\/501100002418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008235","name":"Peking Union Medical College Hospital","doi-asserted-by":"publisher","award":["2022-PUMCH-D-001"],"award-info":[{"award-number":["2022-PUMCH-D-001"]}],"id":[{"id":"10.13039\/501100008235","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10120-026-01744-9","type":"journal-article","created":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T17:46:36Z","timestamp":1786297596000},"page":"1053-1064","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline IL-6 independently predicts severe immune-related toxicity and poor survival in advanced gastric cancer treated with immunotherapy"],"prefix":"10.1007","volume":"29","author":[{"given":"Wanrong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1700-9549","authenticated-orcid":false,"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,9]]},"reference":[{"issue":"3","key":"1744_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10294","key":"1744_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"issue":"2","key":"1744_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1744_CR4","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy versus chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571\u201380.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1744_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"9","key":"1744_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563\u201380.","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"1744_CR7","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","volume":"33","author":"JS Weber","year":"2015","unstructured":"Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33(18):2092\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1744_CR8","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/eji.201040391","volume":"40","author":"A Kimura","year":"2010","unstructured":"Kimura A, Kishimoto T. IL-6: regulator of Treg\/Th17 balance. Eur J Immunol. 2010;40(7):1830\u20135.","journal-title":"Eur J Immunol"},{"issue":"5","key":"1744_CR9","doi-asserted-by":"publisher","first-page":"e1093722","DOI":"10.1080\/2162402X.2015.1093722","volume":"5","author":"BE Lippitz","year":"2016","unstructured":"Lippitz BE, Harris RA. Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis. Oncoimmunology. 2016;5(5):e1093722.","journal-title":"Oncoimmunology."},{"issue":"1","key":"1744_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12916-022-02356-7","volume":"20","author":"C Liu","year":"2022","unstructured":"Liu C, Yang L, Xu H, Zheng S, Wang Z, Wang S, et al. Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. BMC Med. 2022;20(1):187.","journal-title":"BMC Med"},{"key":"1744_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejim.2021.07.016","volume":"93","author":"C Campochiaro","year":"2021","unstructured":"Campochiaro C, Farina N, Tomelleri A, Ferrara R, Lazzari C, De Luca G, et al. Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur J Intern Med. 2021;93:87\u201394.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"1744_CR12","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/1078155217745144","volume":"25","author":"CR Stroud","year":"2019","unstructured":"Stroud CR, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019;25(3):551\u20137.","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"1744_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.annonc.2024.08.2340","volume":"36","author":"PF Petit","year":"2025","unstructured":"Petit PF, Daoudlarian D, Latifyan S, Bouchaab H, Mederos N, Doms J, et al. Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study. Ann Oncol. 2025;36(1):43\u201353.","journal-title":"Ann Oncol"},{"issue":"1","key":"1744_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41698-023-00380-1","volume":"7","author":"RJ Verheijden","year":"2023","unstructured":"Verheijden RJ, van Eijs MJM, May AM, van Wijk F, Suijkerbuijk KPM. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. npj Precis Oncol. 2023;7(1):41.","journal-title":"npj Precis Oncol"},{"key":"1744_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ejca.2021.08.031","volume":"157","author":"F Dimitriou","year":"2021","unstructured":"Dimitriou F, Hogan S, Menzies AM, Dummer R, Long GV. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. Eur J Cancer. 2021;157:214\u201324.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1744_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","volume":"40","author":"Y Hailemichael","year":"2022","unstructured":"Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022;40(5):509-23 e6.","journal-title":"Cancer Cell"},{"key":"1744_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1553882","volume":"16","author":"H Ma","year":"2025","unstructured":"Ma H, Zhang S, Jiao P, Ding H, Wang F, Zhao Y, et al. Serum IL-6 predicts immunotherapy-related adverse and outcome in advanced gastric and esophageal cancer patients with Anti-PD-1 treatment. Front Immunol. 2025;16:1553882.","journal-title":"Front Immunol"},{"issue":"43","key":"1744_CR18","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1744_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137.","journal-title":"Nat Methods"},{"issue":"12","key":"1744_CR20","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s00262-017-2052-5","volume":"66","author":"XL Fu","year":"2017","unstructured":"Fu XL, Duan W, Su CY, Mao FY, Lv YP, Teng YS, et al. Interleukin 6 induces M2 macrophage differentiation by STAT3 activation that correlates with gastric cancer progression. Cancer Immunol Immunother. 2017;66(12):1597\u2013608.","journal-title":"Cancer Immunol Immunother"},{"key":"1744_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01840","volume":"8","author":"M Jiang","year":"2017","unstructured":"Jiang M, Chen J, Zhang W, Zhang R, Ye Y, Liu P, et al. Interleukin-6 trans-signaling pathway promotes immunosuppressive myeloid-derived suppressor cells via suppression of Suppressor of Cytokine Signaling 3 in breast cancer. Front Immunol. 2017;8:1840.","journal-title":"Front Immunol"},{"issue":"17","key":"1744_CR22","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-18-0118","volume":"78","author":"H Tsukamoto","year":"2018","unstructured":"Tsukamoto H, Fujieda K, Miyashita A, Fukushima S, Ikeda T, Kubo Y, et al. Combined blockade of IL-6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment. Cancer Res. 2018;78(17):5011\u201322.","journal-title":"Cancer Res"},{"issue":"3","key":"1744_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010612","volume":"13","author":"H Jeong","year":"2025","unstructured":"Jeong H, Koh J, Kim S, Yim J, Song SG, Kim H, et al. Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6\/Jak\/Stat3 in PD-L1-high lung cancer. J Immunother Cancer. 2025;13(3):e010612.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"1744_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","volume":"9","author":"SJ Wang","year":"2023","unstructured":"Wang SJ, Dougan SK, Dougan M. Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer. 2023;9(7):543\u201353.","journal-title":"Trends Cancer"},{"issue":"2","key":"1744_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/pros.23726","volume":"79","author":"SH Yu","year":"2019","unstructured":"Yu SH, Maynard JP, Vaghasia AM, De Marzo AM, Drake CG, Sfanos KS. A role for paracrine interleukin-6 signaling in the tumor microenvironment in prostate tumor growth. Prostate. 2019;79(2):215\u201322.","journal-title":"Prostate"},{"issue":"3","key":"1744_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","volume":"33","author":"T Hirano","year":"2021","unstructured":"Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127\u201348.","journal-title":"Int Immunol"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01744-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-026-01744-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01744-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:53:46Z","timestamp":1787896426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-026-01744-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1744"],"URL":"https:\/\/doi.org\/10.1007\/s10120-026-01744-9","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,9]]},"assertion":[{"value":"10 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for this study was obtained from the Medical Ethics Committee of Peking Union Medical College Hospital (Approval Identifier: S-K2098). This study conformed to the principles of the Helsinki Declaration and ethical requirements involving human subjects. Informed consent was not required because of the retrospective design and anonymization of the study.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}